The authors examined the association between the use of diethytstilbestrol during pregnancy and the risk of subsequent fatal breast cancer in a large prospective study of US adults. After 9 years of follow-up, 1,574 cases of fatal breast cancer were observed among 501,536 gravid women who reported no prior history of cancer in 1982. Results from Cox proportional hazards models showed a positive association between a history of diethylstilbestrol exposure (reported by 3.9% of all women) and fatal breast cancer (adjusted rate ratio = 1.34,95% confidence interval 1.06-1.69). This excess risk did not increase over time; women who were exposed more than 35 years ago (rate ratio = 1.35,95% confidence interval 0.97-1.87) were not at greater risk than women who were exposed within the past 35 years (rate ratio = 1.39, 95% confidence interval 1.01-1.93). The positive association was not observed in women who used diethylstilbestrol before age 25 years but was seen at all other ages. The age of study participants did not modify the association between exposure and breast cancer, and there were no significant interactions between ever use of diethylstilbestrol and any of the other potential risk factors included in the analysis. These findings are consistent with those of several other studies of diethylstilbestrol exposure and breast cancer. Am J Epidemiol 1996; 144:645-52.
Diethylstilbestrol, a potent synthetic estrogen, was prescribed in the United States between 1940 and 1970 for a wide range of conditions related to pregnancy (1) (2) (3) . The primary indications for its use were both the treatment of threatened abortions and the prevention of abortions in patients who had had previous pregnancy losses (2, 3) . Estimates of the number of women who received diethylstilbestrol during pregnancy in the United States during the 1940s through the 1960s range from 500,000 to 2 million (4), and estimates of the proportion of the adult female population exposed during the time of peak use range from 5 to 9 percent (4-6). The peak years of exposure occurred in the early 1950s (7) ; its use in pregnancy was banned in the United States in 1971 (8) .
Two factors led to the decline in use and eventual ban of diethylstilbestrol. Results of clinical trials in the early 1950s of the efficacy of this drug did not demonstrate any beneficial effects of its use on pregnancy outcome (9) (10) (11) (12) . More importantly, by the early 1970s, the carcinogenic properties of diethylstilbestrol had become apparent. Several epidemiologic studies demonstrated that its use during pregnancy was associated with an increased risk of vaginal and cervical clear cell adenocarcinoma in prenatally exposed daughters (5) (6) (7) (13) (14) (15) . Concern about the future breast cancer risk in mothers exposed to diethylstilbestrol during their reproductive years has led to five cohort studies: three follow-up studies of the original clinical trial members (16) (17) (18) (19) (20) and two retrospective cohort studies (21) (22) (23) . Four of the five studies have suggested a modest (20-50 percent) increase in breast cancer risk among exposed women with an apparent latency period of 15-20 years (16) (17) (18) (21) (22) (23) ; only one has demonstrated a statistically significant increase (22, 23) . Most of the studies have been limited by small numbers of cases and, with one exception (23) , had average follow-up periods of less than 30 years, thus including many women who had not yet reached an age when breast cancer incidence is high. Finally, the possibility that breast cancer risk among exposed women could increase with increasing follow-up time (22) has not been adequately addressed.
In order to investigate further the risk of breast cancer in women exposed to diethylstilbestrol during pregnancy and to determine if this risk varies across follow-up time, we examined the association of dieth-646 Calle et al.
ylstilbestrol exposure and fatal breast cancer in a large prospective cohort of US women.
MATERIALS AND METHODS
Women in this study were selected from the 676,526 female participants of Cancer Prevention Study II, a prospective mortality study of about 1.2 million American men and women begun by the American Cancer Society in 1982 (24, 25) . Participants were identified and enrolled by over 77,000 volunteers in all 50 states, the District of Columbia, and Puerto Rico. They completed a confidential questionnaire in 1982 that included personal identifiers, demographic characteristics, personal and family history of cancer and other diseases, and various behavioral, environmental, occupational, and dietary exposures. The median age of female study participants in 1982 was 56 years; 75 percent of the women were between 45 and 70 years of age, and none was younger than 30 years.
The vital status of study participants was determined from the month of enrollment through December 31, 1991, using two approaches. Volunteers made personal inquiries in September of 1984, 1986, and 1988 to determine whether their enrollees were alive or deceased and to record the date and place of all deaths. Automated linkage using the National Death Index was used to extend follow-up through December 31, 1991 (26) and to identify deaths among 13,219 (2 percent) women lost to follow-up between 1982 and 1988. At completion of mortality follow-up in December 1991, 615,009 women (90.9 percent) were still living, 59,439 (8.8 percent) had died, and 2,078 (0.3 percent) had follow-up truncated on September 1, 1988 , because of insufficient data for National Death Index linkage. Death certificates were obtained for 97.1 percent of all women known to have died.
Breast cancer deaths were defined as those women who had died through December 31, 1991, with breast cancer (International Classification of Diseases, Ninth Revision, codes 174.0-174.9) (27) as the underlying cause. We excluded from the analysis 3,275 women with incomplete information on race, 56,861 who had prevalent cancer (except nonmelanoma skin cancer) at study entry in 1982, 63,478 who were never pregnant, and 51,376 with missing data on history of diethylstilbestrol use. After 9 years of follow-up, 1,574 eligible cases of fatal breast cancer were observed among 501,536 women (table 1).
In the baseline questionnaire, women completed a section on menstrual and reproductive history that included questions about pregnancies, live births, stillbirths, spontaneous abortions, and diethylstilbestrol use. Specifically, women were asked, "Were you ever given DES (diethylstilbestrol) to prevent miscar- riage?" They were also asked for the age at which they took this drug. No information was collected on the actual dosage administered or on whether it was used during more than one pregnancy. A time-varying covariate, "attained age" (28, p. 337), was defined for each study participant. At each point in time during the follow-up period, attained age was calculated as the age at interview plus time elapsed since the start of follow-up. For each woman, attained age was incremented throughout the followup period until the woman died or was lost to follow-up or until the study ended.
Three definitions of diethylstilbestrol use were investigated for their potential relation with fatal breast cancer: ever use (ever, never); age at use (categorized as <25 years, 25-29 years, 30-34 years, ^35 years); and years since use (categorized as <30, 30-34, 35-39, 5:40) . Years since use was a time-varying covariate (29) , defined as the difference between attained age and age at use.
We used Cox proportional hazards modeling (30) to compute rate ratios and to adjust for other risk factors when assessing the association of diethylstilbestrol use and fatal breast cancer. All Cox models were stratified on single year of age at interview. By including age in the strata statement of the Cox model, we avoided the assumptions of a constant relative hazard across age and an exponential relation between diethylstilbestrol exposure and age (29) . Other potential confounders included in multivariate models were race (white, black, other), a history of breast cancer in a mother or sister (yes or no), a personal history of breast cysts (yes or no), body mass index (weight (kg)/height (m)
2 ) of <26, 26-<29, 5=29, age at first live birth (<20, 20-24, 25-29, ^30 years), spontaneous abortions (none, one, two or more), stillbirths (none, one or more), age at menarche (<12, 12, 13, ^14 years), age at menopause (<45, 45-49, 50-54, or ^55 years, or premenopausal), oral contraceptive use (ever, never), estrogen replacement therapy (ever, never), years of education (<12, 12, 13-<16, ^16), smoking (current, former, never), and alcohol use (none, three drinks per week to less than one drink per day, one drink per day, more than one drink per day, or missing). Rate ratios reported in the text are those obtained from multivariate analyses.
To test whether any of the potential confounders described above modified the association between diethylstilbestrol use and breast cancer, we entered multiplicative interaction terms between diethylstilbestrol use (ever or never) and all other risk factors into the multivariate models. We also assessed whether attained age modified the association (28, p. 337). Attained age was categorized into five age groups (<55 years, 55-59 years, 60-64 years, 65-69 years, and 70 years), and both deaths and person-years at risk were allocated to each attained age category. A given study participant could contribute person-years at risk to more than one age group, depending on the ages attained by that participant during the study period. Statistical significance of the interaction terms was assessed at the p -0.05 level using the likelihood ratio test (28) .
Tests for trend in categorical variables were evaluated by scoring the variable and entering the score as a continuous term in the regression model. The Wald chi-square test was used to test the statistical significance of a linear trend in age at exposure and years since exposure (31) .
RESULTS
A history of diethylstilbestrol use was reported by 3.9 percent of all women in this cohort. Users were on average 27 years old at the time of use, and the calendar years of peak use were [1950] [1951] [1952] [1953] [1954] [1955] [1956] . The end of follow-up, December 31, 1991, represented a mean of 37 years after diethylstilbestrol exposure. Table 2 shows both crude and age-adjusted percentages of women with a history of diethylstilbestrol use across categories of other potential breast cancer risk factors. Use varied considerably across levels of the other covariates, especially for spontaneous abortion, age at interview, education, age at first live birth, and estrogen replacement therapy. Over 8 percent of women who reported a history of one or more spontaneous abortions had used diethylstilbestrol versus about 2 percent of women with no history of spontaneous abortion. Almost 14 percent of women who had a history of two or more spontaneous abortions had used diethylstilbestrol. Users were overrepresented among women aged 50-59 years at the time of study enrollment and underrepresented among very young and very old women. Users also had higher educational attainment, were more likely to be nulliparous or to be older at the time of first birth, and to have used postmenopausal estrogens.
Among all women, a positive association was observed between ever use of diethylstilbestrol and breast cancer mortality (rate ratio (table 3) . When we divided the years since exposure into finer categories, we found no indication of a trend and no suggestion that risk increased with increasing years since exposure (table 3) . In fact, women whose exposure occurred at least 40 years in the past showed no increased risk (rate ratio = 0.99), although this finding was based on a small number (n = 11) of breast cancer deaths.
Attained age did not modify the association between diethylstilbestrol exposure and fatal breast cancer (p for interaction = 0.94) (table 4). There were no significant interactions between ever use of diethylstilbestrol and any of the other potential risk factors included in the analysis (table 4) .
DISCUSSION
These prospective data support the hypothesis that exposure to diethylstilbestrol during pregnancy is associated with an increased risk of fatal breast cancer. This modest, but significant, excess risk did not appear to increase over time; women who were exposed more than 35 years ago were not at greater risk than were women with more recent exposure. This finding is in agreement with the recent report by Colton et al. (23) , the only other study that has examined the effects of diethylstilbestrol exposure more than 30 years after the exposed pregnancy. The magnitude of the observed increased risk, about 35 percent, was similar to that found in several previously published studies (16) (17) (18) (21) (22) (23) .
The increased risk associated with diethylstilbestrol exposure in our cohort was not due to confounding by other potential breast cancer risk factors that we could measure. Risk estimates were virtually unchanged in multivariate models including all potential confounders. Of particular importance was our ability to include a history of spontaneous abortion as a potential confounder in multivariate models. Several studies have suggested that a history of spontaneous abortion may increase the risk of breast cancer (32) (33) (34) , although most studies of this topic do not support a significant positive association (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) . A history of spontaneous abortion is strongly related to diethylstilbestrol use and could confound the association between exposure and breast cancer risk. In our data, a history of spontaneous abortion was not associated with fatal breast cancer (47) , and control for this variable did not alter the estimates of risk. Because diethylstilbestrol is no longer in general use, the significance of these and other similar findings is largely in their potential relevance to current use of exogenous estrogens. It should be noted that the doses of diethylstilbestrol historically administered during pregnancy were massive relative to current doses of estrogen used for replacement therapy or contraception. A typical treatment schedule involved the administration of 5 mg per day beginning in the sixth week of pregnancy and increasing to 125-150 p for trend = 0.24 * Adjusted for age at interview and race. t Adjusted for age at Interview, race, family history of breast cancer, body mass index, education, smoking, alcohol, breast cysts, age at menarche, age at first live birth, age periods stopped, oral contraceptive use, estrogen replacement therapy, and spontaneous abortion.
X Excludes one death and 709 women with missing age at exposure. t The reference category comprised never users of DES at each level of the characteristic. The rate ratio was adjusted for age at interview, race, family history of breast cancer, body mass index, education, smoking, alcohol, breast cysts, age at menarche, age at first live birth, age periods stopped, oral contraceptive use, estrogen replacement therapy, and spontaneous abortion. mg per day in the 35th week, for a total dose of about 12,000 mg over a 4-to 6-month period (2, 17) . Women in the three follow-up studies of original clinical trial members received this standard regimen with total doses over 11,000 mg (16) (17) (18) (19) (20) , while women enrolled in the retrospective cohort studies had somewhat lower total doses, ranging from 1,760 to 8,670 mg (21, 22) . In contrast, the oral dose of conjugated equine estrogens typically prescribed to postmenopausal women to treat symptoms of menopause is 0.625 mg per day. In animals, diethylstilbestrol has been found to be 3-5 times more potent as an estrogen than the natural estrogens (estradiol, conjugated estrogens) when administered orally (1, 48) . Thus, the total Am J Epidemiol Vol. 144, No. 7, 1996 dose of diethylstilbestrol administered during one pregnancy in most cases greatly exceeded the dose of estrogen that would be received in many years of exposure to oral estrogen replacement therapy.
Data on the effects of diethylstilbestrol by dose are very limited. No dose-related data were available in our study. Only one of the available cohort studies had both variability in dose across the women in the study and documentation of individual dose levels (21) . When the association between diethylstilbestrol and breast cancer was examined across three levels of exposure (<l,000 mg, 1,000-4,500 mg, >4,500 mg), no dose-response relation was observed (21) . Even with sufficient data, dose-response trends may prove difficult to document given the uniformly high doses that were actually used (22) . Thus, the relevance of the effects of very high dose diethylstilbestrol regimens to the potential effects of current low levels of exogenous estrogens remains somewhat unclear. However, our study and similar studies provide some reassurance that no large increases in breast cancer risk are observed even with large doses of exogenous estrogens given during pregnancy, a time when breast tissue may be particularly vulnerable to carcinogenic exposure.
One limitation of our study is the reliance on mortality due to breast cancer rather than incidence to identify disease. Thus, our results reflect the effect of diethylstilbestrol on either breast cancer incidence, survival, or both. However, given that our results are in close agreement with those of several other incidence studies of this topic, we have no reason to suspect that these results reflect an association of diethylstilbestrol with survival only. The prospective design of our study and the exclusion of women with cancer at baseline eliminate the possibility that disease status might bias the reporting of diethylstilbestrol exposure during pregnancy. Also, our study was able to control adequately for other important breast'cancer risk factors. Finally, study participants are, on average, more educated and affluent than the US population as a whole. While these differences may influence comparisons of absolute rates of disease or exposure between this population and the US population, they are unlikely to compromise internal validity.
The modest increase in breast cancer risk observed in this and other studies could represent a true causal effect or could be due to bias. Relative risks in this low range may occur as a result of bias in study design or execution, or they may be due to residual uncontrolled confounding. While bias or residual confounding cannot be ruled out, the similarity of results across several different studies, coupled with the known carcinogenic potential of diethylstilbestrol (49) , supports the hypothesis that high-dose exposure to this drug during pregnancy has a weak carcinogenic effect on the breast.
In summary, our results add further support for the association between diethylstilbestrol exposure during pregnancy and subsequent breast cancer. They also suggest that the modest increase in risk will not increase with increasing follow-up of exposed women. These findings are consistent with those of several other studies of diethylstilbestrol exposure and breast cancer (16) (17) (18) (21) (22) (23) , including the one other cohort study that has followed women for more than 30 years after their exposure (23) . While mammography screening recommendations for women who have been exposed to diethylstilbestrol are essentially the same as for all women (50), awareness of their small increased risk may provide additional motivation for exposed women to follow age-appropriate screening guidelines.
